Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Atadja

Showing results (31-40 of 102) with videos related to

Pageof 11
Sort By:
Haematologica|April 13, 2004
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemiaAnnette Romanski, Biserka Bacic, Gesine Bug, et al.
Molecular Cancer Therapeutics|January 24, 2007
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanomaYukihiko Kato, Brenda C Salumbides, Xiao-Fei Wang, et al.
International Journal of Cancer|February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistanceWenlin Shao, Joseph D Growney, Yun Feng, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Blood|March 20, 2008
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cellsAnna Scuto, Mark Kirschbaum, Claudia Kowolik, et al.
Plos One|December 2, 2011
Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profilingShijun Fu, Qi Fei, Hua Jiang, et al.
Blood|October 30, 2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Prince George, Purva Bali, Srinivas Annavarapu, et al.
Blood|January 21, 2010
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanismsElke De Bruyne, Tomas J Bos, Frans Schuit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Warren Fiskus, Yuan Ren, Alex Mohapatra, et al.
Cancer Research|June 3, 2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistancePatricia Maiso, Xonia Carvajal-Vergara, Enrique M Ocio, et al.
Pageof 11

Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Haematologica|April 13, 2004
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemiaAnnette Romanski, Biserka Bacic, Gesine Bug, et al.
Molecular Cancer Therapeutics|January 24, 2007
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanomaYukihiko Kato, Brenda C Salumbides, Xiao-Fei Wang, et al.
International Journal of Cancer|February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistanceWenlin Shao, Joseph D Growney, Yun Feng, et al.
Plos One|November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Blood|March 20, 2008
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cellsAnna Scuto, Mark Kirschbaum, Claudia Kowolik, et al.
Plos One|December 2, 2011
Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profilingShijun Fu, Qi Fei, Hua Jiang, et al.
Blood|October 30, 2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Prince George, Purva Bali, Srinivas Annavarapu, et al.
Blood|January 21, 2010
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanismsElke De Bruyne, Tomas J Bos, Frans Schuit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Warren Fiskus, Yuan Ren, Alex Mohapatra, et al.
Cancer Research|June 3, 2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistancePatricia Maiso, Xonia Carvajal-Vergara, Enrique M Ocio, et al.
Pageof 11